Iconovo AB

The US Food and Drug Administration has given a positive nod to the potential generic submission and substitutability of Iconovo ’s proprietary inhaler ICOpre with the original drug Breo Ellipta (flu

Iconovo has set GLP-1s as its new goal and announced the start of development for a nasally administrated semaglutide. The Swedish inhalation specialist plans to develop the nasal semaglutide inhaler

The European Medicines Agency’s pharmacovigilance committee, the PRAC, has issued a series of safety updates and recommendations for changes to the product information for a number of COVID-19 vaccine

A candidate COVID-19 vaccine developed by the Spanish company, HIPRA, has begun a rolling review at the European Medicines Agency for use as a booster in adults who have already been fully vaccinated